Quality of Life in European Patients with Addison's Disease: Validity of the Disease-Specific Questionnaire AddiQoL

被引：78

作者：

Oksnes, Marianne ^{[1
]}

Bensing, Sophie ^{[3
,4
]}

Hulting, Anna-Lena ^{[3
]}

Kaempe, Olle ^{[4
]}

Hackemann, Annika ^{[5
]}

Meyer, Gesine ^{[5
]}

Badenhoop, Klaus ^{[5
]}

Betterle, Corrado ^{[6
]}

Parolo, Anna ^{[6
]}

Giordano, Roberta ^{[7
]}

Falorni, Alberto ^{[8
]}

Papierska, Lucyna ^{[9
]}

Jeske, Wojciech ^{[9
]}

Kasperlik-Zaluska, Anna A. ^{[9
]}

Chatterjee, V. Krishna K. ^{[10
]}

Husebye, Eystein S. ^{[1
,2
]}

Lovas, Kristian ^{[1
,2
]}

机构：

[1] Univ Bergen, Inst Med, N-5021 Bergen, Norway

[2] Haukeland Hosp, Dept Med, N-5021 Bergen, Norway

[3] Karolinska Inst, Dept Mol Med & Surg, SE-17177 Stockholm, Sweden

[4] Uppsala Univ, Dept Med Sci, SE-75105 Uppsala, Sweden

[5] Goethe Univ Frankfurt, Univ Hosp, Dept Med 1, Div Endocrinol & Diabetol, D-60325 Frankfurt, Germany

[6] Univ Padua, Endocrine Unit, Dept Med & Surg Sci, I-35122 Padua, Italy

[7] Univ Turin, Dept Clin & Biol Sci, I-10126 Turin, Italy

[8] Univ Perugia, Dept Internal Med, I-06126 Perugia, Italy

[9] Med Ctr Postgrad Educ, Endocrinol Clin, Warsaw, Poland

[10] Univ Cambridge, Inst Metab Sci, Cambridge CB2 0QQ, England

来源：

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM | 2012年 / 97卷 / 02期

关键词：

SUBJECTIVE HEALTH-STATUS; GLUCOCORTICOID REPLACEMENT THERAPY; MODIFIED-RELEASE HYDROCORTISONE; GROWTH-HORMONE DEFICIENCY; RASCH MEASUREMENT MODEL; ADRENAL INSUFFICIENCY; QOL-AGHDA; DEHYDROEPIANDROSTERONE REPLACEMENT; ADULTS; TRIAL;

D O I：

10.1210/jc.2011-1901

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Context: Patients with Addison's disease (AD) self-report impairment in specific dimensions on well-being questionnaires. An AD-specific quality-of-life questionnaire (AddiQoL) was developed to aid evaluation of patients. Objective: We aimed to translate and determine construct validity, reliability, and concurrent validity of the AddiQoL questionnaire. Methods: After translation, the final versions were tested in AD patients from Norway (n = 107), Sweden (n = 101), Italy (n = 165), Germany (n = 200), and Poland (n = 50). Construct validity was examined by exploratory factor analysis and Rasch analysis, aiming at unidimensionality and fit to the Rasch model. Reliability was determined by Cronbach's coefficient-alpha and Person separation index. Longitudinal reliability was tested by differential item functioning in stable patient subgroups. Concurrent validity was examined in Norwegian (n = 101) and Swedish (n = 107) patients. Results: Exploratory factor analysis and Rasch analysis identified six items with poor psychometric properties. The 30 remaining items fitted the Rasch model and proved unidimensional, supported by appropriate item and person fit residuals and a nonsignificant chi(2) probability. Crohnbach's alpha-coefficient 0.93 and Person separation index 0.86 indicate high reliability. Longitudinal reliability was excellent. Correlation with Short Form-36 and Psychological General Well-Being Index scores was high. A shorter subscale comprising eight items also proved valid and reliable. Testing of AddiQoL-30 in this large patient cohort showed significantly worse scores with increasing age and inwomencompared with men but no difference between patients with isolated AD and those with concomitant diseases. Conclusion: The validation process resulted in a revised 30-item AddiQoL questionnaire and an eight-item AddiQoL short version with good psychometric properties and high reliability. (J Clin Endocrinol Metab 97: 568-576, 2012)

引用

页码：568 / 576

页数：9